Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Inventory (2016 - 2025)

Integra Lifesciences Holdings' Change in Inventory history spans 17 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 486.14% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $46.8 million, up 66.12%, while the annual FY2025 figure was $46.8 million, 66.12% up from the prior year.
  • Change in Inventory for Q4 2025 was $3.3 million at Integra Lifesciences Holdings, down from $23.3 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $25.4 million in Q1 2023 and bottomed at -$9.0 million in Q4 2021.
  • The 5-year median for Change in Inventory is $6.4 million (2021), against an average of $7.9 million.
  • The largest YoY upside for Change in Inventory was 529.87% in 2021 against a maximum downside of 418.49% in 2021.
  • A 5-year view of Change in Inventory shows it stood at -$9.0 million in 2021, then soared by 152.17% to $4.7 million in 2022, then skyrocketed by 250.84% to $16.4 million in 2023, then plummeted by 96.53% to $570000.0 in 2024, then surged by 486.14% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Change in Inventory are $3.3 million (Q4 2025), $23.3 million (Q3 2025), and $6.4 million (Q2 2025).